Replies to post #853 on Nymox Pharmaceutical Corp (NYMXF)

[davidsson10]

"Chalk up Nymox's rebound to persistent promotion and the willingness of traders to latch onto any stock with momentum. The company is certainly not surviving on fundamentals. Fexapotide is worth nothing. Including the most recent financing, Nymox has approximately 5 cents per share in cash. Yet at $4.34 per share, the company's market value exceeds $240 million."

[NotRichYet2]

That article writer , Adam Feuerstein , did a royal job of DAMMING the NYMX company's new drug and findings. Might as well have come outright and called them LYING FRAUDS and the drug in there PR release this week a total ly complete FAILURE. If AF is right I see clase action suits againt the company (big time). If AF published that article just to drop the stock PPS with no real valide backup of his own , company should sue him. JMHO